Cencora's quality profile sits below the minimum acceptable threshold — free cash flow is negative, margins have compressed sharply to -30.1%, and leverage is elevated — while a perfect four-quarter beat streak and 8.4% upside to the analyst target create a tension between business-quality concerns and near-term earnings execution.
Thesis pillars
- Value Trap Margin Compression Leverage↓Deteriorating
- Quality Below Minimum Threshold↓Deteriorating
- Negative Free Cash Flow Red Flag↑Improving
- +1 more pillar — see the Why tab for full reasoning
Cencora, Inc. (COR) Stock Analysis
Range Bound setup
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $316.85: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Below long-term trend.
Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals, pharmacies, physicians, and veterinarians across the U.S. and select global markets through two segments: U.S. Healthcare Solutions and International Healthcare... Read more
Sell if holding. Engine safety override at $316.85: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, news boost analyst 0.70, news boost analyst cluster(3), earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-08-13Recent Developments — Cencora, Inc.
Latest news
- NEWS Joel Isaacson & Co. LLC Buys Shares of 22,815 Cencora, Inc. $COR - MarketBeat — MarketBeat neutral
- NEWS Cencora (COR) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Cencora (COR): 3 Reasons We Love This Stock - StockStory — StockStory positive
- NEWS Why Is Cencora Stock Trading Lower On Wednesday? - Benzinga — Benzinga negative
- NEWS Cencora Stock (COR) Opinions on Q2 Earnings Release - Quiver Quantitative — Quiver Quantitative neutral
Generated 2026-08-14T17:32:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop ten customers66%10-K Item 1A: 'Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025'
- MEDIUMCustomerWalgreens and Boots25%10-K Item 1A: 'Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025'
- LOWCustomerEvernorth Health Services13%10-K Item 1A: 'Evernorth Health Services accounted for approximately 13% of our revenue in fiscal 2025'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02HIGHCFO James F. Cleary announced retirement as EVP and CFO effective June 30, 2026; no successor named at time of filing. Retirement not result of any disagreement with company operations or practices.SEC filing →
- 2026-05-29Item 5.02MEDIUMEva C. Boratto appointed EVP and CFO effective June 29, 2026, succeeding retiring CFO James F. Cleary. Cleary to serve in advisory capacity through end of 2026. Boratto most recently CFO of Bath & Body Works since August 2023.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $316.85: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $294.69. Score 5.5/10, moderate confidence.
Take-profit target: $324.15 (+3.2% upside). Prior stop was $294.69. Stop-loss: $294.69.
Concentration risk — Customer: top ten customers (66.0%); Quality below floor (3.9 < 4.0).
Cencora, Inc. trades at a P/E of 24.2 (forward 16.8). TrendMatrix value score: 6.8/10. Verdict: Sell.
20 analysts cover COR with a consensus score of 4.0/5. Average price target: $373.
What does Cencora, Inc. do?Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals,...
Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals, pharmacies, physicians, and veterinarians across the U.S. and select global markets through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. Top-10 customers represented approximately 66% of fiscal 2025 revenue, with Walgreens and Boots at roughly 25% and Evernorth Health Services at roughly 13%.